Journals / Ege Tıp Dergisi / 2017 / Cilt: 56 - Sayı: 1

Lafora disease

Lafora hastalığı

Pages
38–40
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In our case a 17-year- old woman who was diagnosed as Lafora disease presented in light of the literatüre.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Lafora disease is a rare, autosomal recessive form of progressive myoclonic epilepsy, characterized by myclonic seizures, cerebellar ataxia, rapidly progressive dementia and poor prognosis.
📊
Key Findings & Data:The symptoms typically start between the ages of 12 and 17 years in a previously normal mental and motor developing child.
💡
Conclusion & Impact:In our case a 17-year- old woman who was diagnosed as Lafora disease presented in light of the literatüre.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Lafora disease is a rare, autosomal recessive form of progressive myoclonic epilepsy, characterized by myclonic seizures, cerebellar ataxia, rapidly progressive dementia and poor prognosis. The symptoms typically start between the ages of 12 and 17 years in a previously normal mental and motor developing child. The diagnosis is made by clinical signs, electroencephalographic findings and muscle and skin biopsies. In our case a 17-year- old woman who was diagnosed as Lafora disease presented in light of the literatüre.

Özet

Lafora hastalığı, miyoklonik nöbetler, serebellar ataksi, hızlı ilerleyici demans ve kötü prognoz ile karakterize, progresif myoklonik epilepsi sendromlarının nadir görülen, otozomal resesif bir formudur. Semptomlar, tipik olarak öncesinde motor ve mental gelişim açısından normal olan çocuklarda, 12- 17 yaşlar arasında başlar. Hastalığın tanısı klinik özellikler, elektroensefalografi bulguları, kas ve deri biyopsileri ile konulmaktadır. Çalışmamızda, Lafora hastalığı tanısı konulan, 17 yaşında bayan hasta literatür eşliğinde sunulmuştur.

🔖

Cite This Article

EHI, Y., ÖZLECE, H. K., GEZGİN, İ., ADALI, Y., HÜSEYİNOĞLU, Ü. (2017). Lafora disease. Ege Tıp Dergisi, Cilt: 56 - Sayı: 1, 38–40. https://ajindex.com/articles/222713

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Ismihanoglu B, Yalcin D, Tanik C, Forta H. Lafora body disease: Report of two cases. Epilepsi 2006;12(2):78-84
  2. Busard BL, Renier WO, Gabreëls FJ, Jaspar HH, van Haelst UJ, Slooff JL. Lafora’s disease. Comparison of inclusion bodies in skin and in brain. Arch Neurol 1986;43(3):296-9
  3. Striano P, Zara F, Turnbull J, et al. Typical progression of myoclonic epilepsy of the Lafora type: A case report. Nat Clin Pract Neurol 2008;4(2)106-11
  4. Panayiotopoulos CP.A Clinical Guide to Epileptic Syndromes and Their Treatment. 2nd ed., Springer, 2007
  5. Baykan B, Özemir ZA. Progresif myoklonik epilepsiler: In: Bora I, Yeni N, Gürses C, (eds). Epilepsi; İstanbul; Nobel Tıp Kitabevi 2008:271-90
  6. Acharya JN, Satishchandra P, Asha T, Shankar SK. Lafora’s disease in south India: A clinical, electrophysiologic, and pathologic study. Epilepsia 1993;34(3):476-87
  7. Gomceli YB, Erdal A, Kutlu G, Inan LE. Two siblings diagnosed as Lafora disease. Turk Norol Derg 2010;16(1):40-6
  8. Dirani M, Nasreddine W, Abdulla F, Beydoun A. Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy Behav Case Reports 2014;2:164-6
  9. Pederson BA, Turnbull J, Epp JR, et al. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Ann Neurol 2013;74(2):297-30.